Abstract
Glucose transporters play key roles in the homeostatic control of brain functions.
In the present study, we examined the effect of fluoxetine, a selective serotonin
reuptake inhibitor, and pergolide, a dopamine D receptor agonist, on the gene expression
levels of glucose transporters in the mouse brain. mRNAs for 8 sodium-independent
glucose transporters (GLUTs), other than GLUT4 and GLUT9, and sodium-dependent glucose
transporter 1 (SGLT1) were confirmed to be expressed in brain tissue. Fluoxetine and
pergolide significantly increased the expression levels of mRNAs for GLUT1 and GLUT10
in the brain. Furthermore, the expression of GLUT6 in tissue was increased by administering
pergolide to mice. On the other hand, fluoxetine and pergolide had no effect on the
expression levels of mRNAs for the other GLUTs and SGLT1. Therefore, we concluded
that the gene expression of several GLUT isoforms in the mouse brain was affected
by the treatment with fluoxetine and pergolide.
